
{{header
 | title      = Cody Miller Initiative for Safer Prescriptions Act ( HR1608 ; 113th Congress)
 | author     = [[Bill Owens (congressman)]]
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 04
 | day        = 17
 | notes      = ''{{USBill|113|hr|1608}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Cody Miller Initiative for Safer Prescriptions Act ( HR1608 ; 113th Congress)
 | bill       = 1608
 | billtype   = hr
 | purpose    = To require the Secretary of Health and Human Services to promulgate regulations regarding the authorship, content, format, and dissemination of Patient Medication Information to ensure patients receive consistent and high-quality information about their prescription medications and are aware of the potential risks and benefits of prescription medications.
 | wikipedia  =
}}

113 HR 1608 IH: Cody Miller Initiative for Safer Prescriptions ActU.S. House of Representatives2013-04-17text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 1608}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|April 17, 2013}}


{{Center|
[[w:Bill Owens (congressman)|Mr. Owens]] introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}


{{Center|A BILL}}

To require the Secretary of Health and Human Services to promulgate regulations regarding the authorship, content, format, and dissemination of Patient Medication Information to ensure patients receive consistent and high-quality information about their prescription medications and are aware of the potential risks and benefits of prescription medications.

={{anchor|HB773DC02B2C54AFAB6E4E27455B9C893}}Section 1. Short title=

This Act may be cited as the“Cody Miller Initiative for Safer Prescriptions Act”.

={{anchor|H55F490FBB29C4F75BB748BB5443A3347}}Sec. 2. Patient medication information for prescription drugs=

 Chapter V of the Federal Food, Drug, and Cosmetic Act([http://www.law.cornell.edu/uscode/text// [http://www.law.cornell.edu/uscode/text/21/351 21 U.S.C. 351 et seq.] ] )is amended by inserting after section 505Dthe following:

<blockquote>

={{anchor|HAD2253C6AC8B4BC6ABC6B665A642A1AC}}Sec. 505E. Patient medication information for prescription drugs=



=={{anchor|HEEA084337D004A22B04DCBC96A7DDA2E}}(a) In general– ==

Not later than 2 years after the date of enactment of this section, the [[w:Department of Health and Human Services|Secretary]] shall issue regulations regarding the authorship, content, format, and dissemination requirements for patient medication information (referred to in this section as PMI ) for drugs subject to section 503(b)(1).

=={{anchor|HB6E2356BF3C94931BB9F312F6AC0B944}}(b) Content– ==

The regulations promulgated under subsection (a)shall require that the PMI with respect to a drug—
:(1) be scientifically accurate and based on the professional labeling approved by the Secretary and authoritative, peer-reviewed literature; and
:(2) includes nontechnical, understandable, plain language that is not promotional in tone or content, and contains at least—
::(A) the established name of drug, including the established name of such drug as a listed drug (as described in section 505(j)(2)(A)) and as a drug that is the subject of an approved abbreviated new drug application under section 505(j)or of an approved license for a biological product submitted under section 351(k) of the Public Health Service Act, if applicable;
::(B) drug uses and clinical benefits;
::(C) general directions for proper use;
::(D) contraindications, common side effects, and most serious risks of the drug, especially with respect to certain groups such as children, pregnant women, and the elderly;
::(E) measures patients may be able to take, if any, to reduce the side effects and risks of the drug;
::(F) when a patient should contact his or her health care professional;
::(G) instructions not to share medications, and, if any exist, key storage requirements, and recommendations relating to proper disposal of any unused portion of the drug; and
::(H) known clinically important interactions with other drugs and substances.

=={{anchor|HEA1803EB3EC84E178D73C6EC60AA475E}}(c) Timeliness, consistency, and accuracy– ==

The regulations promulgated under subsection (a)shall include standards related to—
:(1) performing timely updates of drug information as new drugs and new information becomes available;
:(2) ensuring that common information is applied consistently and simultaneously across similar drug products and for drugs within classes of medications in order to avoid patient confusion and harm; and
:(3) developing a process, including consumer testing, to assess the quality and effectiveness of PMI in ensuring that PMI promotes patient understanding and safe and effective medication use.

=={{anchor|H30AFA2E286424FB7AFD0EDCCACFE0791}}(d) Electronic repository– ==

The regulations promulgated under subsection (a)shall provide for the development of a publicly accessible electronic repository for all PMI documents and content to facilitate the availability of PMI..
</blockquote>


={{anchor|H3B6BE4D679DC487A92BAF9A062ACB5B4}}Sec. 3. Publication on internet Web site=

The [[w:Department of Health and Human Services|Secretary of Health and Human Services]] shall publish on the Internet Web site of the Food and Drug Administration a link to the Daily Med Web site (http://dailymed.nlm.nih.gov/dailymed) (or any successor Web site).
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
